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A B S T R A C T
It is well known that age-related macular degeneration (AMD), besides glaucoma and diabetic retinopathy, represents
a major cause of low vision and blindness throughout the world. In this study, specific causal factors of AMD are ana-
lyzed, emphasizing the causal role and effects of sunlight, no matter which part of its spectrum, in a longer exposition
through life. The accent is also put on the influence of lifestyle as well as vitamin and antioxidants supplementation in
development or prevention of AMD.
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Introduction
Age-related macular degeneration (AMD) is a major
public health issue. Prevalence of AMD among persons
older than 65 years is 8% and increases with age. In this
condition, the central portion of the retina (the macula)
deteriorates, and central vision can be lost. Central vi-
sion is the »high-definition« vision that is required for
reading, driving, watching television, recognizing people
and performing many other activities of daily of living.
Peripheral vision generally remains intact, although re-
cent references concluded that is peripheral retina at-
tacked too1,2 and elderly persons with age-related macu-
lar degeneration rarely require white canes or guide
dogs. However, they have been found to have lower qual-
ity-of life scores than persons for example with chronic
obstructive pulmonary disease or chronic cardiovascular
diseases. With the continued growth of the elderly popu-
lation in Europe, family physicians are frequently asked
about vision and macular degeneration. As life expec-
tancy continues to increase, age-related macular degen-
eration will become an increasingly important problem.
There are two forms of the disease: atrophic, which is
more prevalent (80-90% of AMD cases) and exudative,
which is characterized by choroidal neovascularization
(CNV; 10-20% of AMD cases). Elderly persons are con-
cerned about losing independence and mobility. Studies
have shown that loss of central visual acuity leads to a re-
duction of daily activities and mobility in the elderly.
Loss of central visual acuity also increases the risks of
falls, fractures and depression in this population.
Epidemiology
Age-related macular degeneration has been examined
in many population-based epidemiologic studies (Table
1). Few studies have evaluated the incidence of age-re-
lated macular degeneration. In the Beaver Dam Eye
Study3 pure geographic atrophy (late age-related macu-
lar degeneration) was 16.6 times more likely to develop
in persons 75 years of age than in persons who were
younger at baseline. The incidence of exudative changes
increased from zero percent in persons less than 55 years
of age to 1.8 % in persons 75 years or older at baseline.
Pathophysiology
The pathophysiology of age-related macular degener-
ation is still under investigation4. The location of the dis-
ease also remains a subject of debate. Some investigators
believe that the disease resides in the neural retina (rods
and cones), whereas others are studying the retinal pig-
ment epithelium (the layer of cells that provide nutrition
to the rods and cones).
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Materials and Methods
To study the natural history of dry type of age-related
macular degeneration (AMD) and search for a sensitive
method for detecting the development of the disease, the
fundus fluorescein angiography, visual acuity, OCT, elec-
troretinogram and FM 100-hue test were used to exam-
ine 75 eyes. These examinations were taken at least
twice during the follow-up periods. The average age was
63.2 years (50-80 years). The average follow-up was 29.8
months with a range of 3-74 months.
Results
It was shown that there were no statistically signifi-
cant differences in the macular lesions, OCT and electro-
retinogram between the initial examinations and after
follow-up (p>0.05). 91.14% of the eyes maintained good
visual acuity during the follow-up. Subretinal neovascu-
larization developed only in one of the eyes. The total er-
ror score of FM 100-hue test had a statistically signifi-
cant difference between the initial test and the test taken
two years afterwards (p<0.01). It was suggested that
most of the dry type of AMD had a favorable prognosis
and that color visual test was a sensitive method for
monitoring the development of dry type of AMD.
Discussion and Conclusion
Risk factors
Contributing factors for development of macular de-
generation include:
¿ Age. In Europe, macular degeneration is the lead-
ing cause of severe vision loss in people age 60 and
older,but is possible in younger1,2.
¿ Family history of macular degeneration. If someone
in your family had macular degeneration, your odds
of developing macular degeneration are higher. In
recent years, researchers have identified some of
the genes associated with macular degeneration. In
the future, genetic screening tests may be helpful
for assessing early risk of the disease.
¿ Race. Macular degeneration is more common in
whites than it is in other groups, especially after
the age of 75.
¿ Sex. Women are more likely than men to develop
macular degeneration, and because they tend to
live longer, women are more likely to experience the
effects of severe vision loss from the disease.
¿ Cigarette smoking. Exposure to cigarette smoke
doubles your risk of macular degeneration. Ciga-
rette smoking is the single most preventable cause
of macular degeneration.
¿ Obesity. Being severely overweight increases the
chance that early or intermediate macular degener-
ation will progress to the more severe form of the
disease.
¿ Light-colored eyes. People with light-colored eyes
appear to be at greater risk than do those with
darker eyes.
¿ Exposure to sunlight. Although the retina is more
sensitive to shorter wavelengths of light, including
ultraviolet (UV) light, only a small percentage of ul-
traviolet light actually reaches the retina. Most ul-
traviolet light is filtered by the transparent outer
surface of your eye (cornea) and the natural crystal-
line lens in your eye. Some experts believe that
long-term exposure to ultraviolet light may increa-
se your risk of developing macular degeneration,
which was especially proved by Vojnikovi} B. in re-
cent clinical examination1,2.
¿ Low levels of nutrients. This includes low blood lev-
els of minerals, such as zinc, and of antioxidant vi-
tamins, such as A, C and E. Antioxidants may pro-
tect your cells from oxygen damage (oxidation),
which may partially be responsible for the effects of
aging and for the development of certain diseases
such as macular degeneration.
¿ Cardiovascular diseases. These include high blood
pressure, stroke, heart attack and coronary artery
disease with chest pain (angina).
Signs and Sympthoms
AMD leads to a blind spot in the center of your visual
field5-8. Other signs and symptoms include:
¿ The need for increasingly bright light when reading
or doing close work,
¿ Printed words that appear distorted or increasingly
blurred,
¿ Colors that seem washed out and dull,
¿ A gradual haziness of your overall vision,
¿ Difficulty seeing when moving from a bright room
to a dimly lit room.
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TABLE 1
EPIDEMIOLOGICAL STUDIES OF AGE-RELATED MACULAR DEGENERATION (DRY AND EXUDATIVE FORM)
– DISTRIBUTION BY AGE GROUPS (%)
Study/age 55–64 65–74 75–84 85+
Beaver Dam (USA) 4756 patients 16.7 (0.5)* 25.3 (1.4)* 41.7 (6.9)* 48.7 (13,5)*
Rotterdam (Netherlands) 6411 patients 2.5 (0.1)* 9.9 (0.7)* 16.7 (3.2)* 29.8 (11.6)*
Blue Mountains (Australia) 3585 patients 2.8 (0.2)* 9.2 (0.7)* 20.9 (5.4)* 46.6 (18.5)*
* percentages for exudative form are given in parentheses.
If AMD develops in one eye and not the other, it may
not be as noticeable, as your good eye compensates for
the weak one. It’s when AMD develops in both eyes that
your vision is dramatically affected.
Diagnostic tests
Diagnostic tests for macular degeneration may in-
clude:
¿ Eye examination. The presence of drusen and mot-
tled pigmentation in the macula as a sign of incipi-
ent AMD. The eye examination includes a simple
test of your central vision and may include testing
with an Amsler grid. Regular screening examina-
tions can detect early signs of macular degeneration
before the disease leads to vision loss.
¿ Angiography and fundus photography. Fluorescein
angiography can be used to confirm the diagnosis
and to help determine whether a patient has the
atrophic or exudative form of the disease. In most
instances, this modality is employed to determine
whether an eye with exudative disease is eligible for
laser treatment. Instead of fluorescein, a dye called
indocyanine green is, used. This test provides infor-
mation that complements the findings obtained
through fluorescein angiography.
¿ Optical coherence tomography. This noninvasive
imaging test helps identify and display areas of reti-
nal thickening or thinning. Such changes are asso-
ciated with macular degeneration. This test can
also reveal the presence of abnormal fluid in and
under the retina or the RPE. It’s often used to help
monitor the response of the retina to macular de-
generation treatments.
¿ Visual field analyses: peripheral and meridian
thresholds examination is obligatory in diagnostic
and developing of AMD.
Hallucinations
Additionally, some people with macular degeneration
may experience visual hallucinations as their vision loss
becomes more severe. These hallucinations may include
unusual patterns, geometric figures, animals or even
faces. In fact, they’re so common that there’s a name for
this phenomenon — Charles Bonnet syndrome.
Age-related macular degeneration is a clinical diagno-
sis that is usually based on the presence of visual distur-
bances and characteristic findings on dilated examina-
tion of the macula. The disease is usually classified as
early or late. Late disease can be divided into atrophic
(dry) and exudative (wet) forms. In early disease, the
macula shows yellowish colored subretinal deposits called
»drusen« and/or increased pigment. Drusen are thought
to be byproducts of retinal pigment epithelium dysfun-
ction9. In most eyes with early disease, visual acuity re-
mains stable for many years, and loss of vision is usually
gradual. Late disease (atrophic and exudative) can lead
to significant loss of vision. In atrophic disease, the
macula usually shows areas of depigmentation. In the
exudative form, fluid can accumulate underneath the
retina, as pigment epithelial detachments or subretinal
neovascularization, and loss of vision is usually sudden.
The Amsler’s grid is an effective tool for detecting the
progression of age-related macular degeneration. The pa-
tient is given a copy of the grid and is instructed to focus
one eye on the center dot in the grid from a distance of 35
cm (12 in) with the other eye covered; the procedure is
then repeated for evaluation of the other eye. The pa-
tient performs this test daily at home and is instructed to
call the physician if line distortions or scotomas are de-
tected and persist for one or two days.
There’s no treatment available to reverse dry macular
degeneration. Dry macular degeneration usually pro-
gresses slowly, and many people with the condition are
able to live relatively normal, productive lives, especially
if only one eye is affected. Dry macular degeneration can,
however, develop into the more rapidly progressive wet
type of macular degeneration at any time.
Laser photocoagulation is the mainstay of treatment
for CNV, although less than 30% of persons with CNV
can benefit from it3. Photodynamic therapy (PDT)10, a
new treatment for CNV, reduces the risk of vision loss in
forms with predominantly visible lesions. Several other
new procedures (antiVGF drugs) are also under develop-
ment. Rehabilitation and low-vision aids are useful pal-
liative interventions when there is a residual visual
acuity.
Nutrition
Numerous observational studies have suggested that
nutrition plays an important role in age-related macular
degeneration11-14. In one observational study, 30 patients
who ate a diet high in fruits and vegetables, especially
green leafy vegetables such as spinach and kale, were
shown to have a lower risk of exudative disease. Al-
though observational studies have supported the value of
eating foods that are high in antioxidants, clinical trials
have provided no evidence for antioxidant supplementa-
tion in pill form. Furthermore, results from clinical trials
of beta-carotene prophylaxis in Finnish smokers asbes-
tos workers suggested that caution should be exercised
in taking pharmacologic dosages of any antioxidant. In
these trials, the risks of lung cancer and death were
greater in patients taking betacarotene than in those
who received placebo. Researchers now believe that sup-
plementing carotenoids in pill form maybe potentially
harmful. Increasing evidence indicates that supplemen-
tation with one carotenoid may lead to reduced serum
levels of other carotenoids. Because there are more than
50 naturally occurring carotenoids, family physicians
need to be confident about choosing the »right« nutrient
for supplementation: supplementing with the »wrong«
carotenoid may lead to lower levels of a needed nutrient.
Taking a high-dose formulation of antioxidants and zinc
may reduce progression of dry macular degeneration to
advanced macular degeneration. The National Eye Insti-
tute-sponsored Age-Related Eye Disease Study (AREDS)
showed that a daily supplement of 500 milligrams (mg) of
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vitamin C, 400 international units (IU) of vitamin E, 15
mg of beta carotene (often as vitamin A — up to 25,000
IU), 80 mg of zinc (as zinc oxide) and 2 mg of copper (as
cupric oxide) reduced the risk of progressing to moderate
or severe vision loss by up to 25%.
Psychosocial Impact of Age-Related Macular
Degeneration
With increasing loss of central vision, patients lose
their ability to read and to conduct certain activities of
daily living. Working elderly patients may worry about
losing their income or their ability to achieve life goals15–17.
Patients may also find that their self-image changes from
that of a responsible, active person to that of a person
who must depend on others for help. With changes in
their ability to function independently, elderly patients
may have additional expenses for help with daily activi-
ties and travel. Along with the ophthalmologist, the fam-
ily physician will need to monitor the mental health of
the patient with age-related macular degeneration. Par-
tially sighted persons may have difficulty adjusting to
their decreased vision and may experience higher levels
of anxiety and loneliness than those who are totally
blind.
Elderly persons with macular degeneration will re-
quire help with simple tasks such as cooking (e.g. reading
recipes and finding ingredients), paying bills and taking
medications. As they become unable to drive, they will
need help to make to medical appointments and visits
with friends and family, contacts that are crucial in pre-
venting isolation and subsequent depression.
Vision Rehabilitation
Patients should be encouraged to consider ways to
maximize their remaining vision so that they can master
some daily activities. Low-vision professionals can be of
great service in assessing residual vision, recommending
optical aids and devices, and providing training in the op-
timal use of these aids. Social workers should be con-
tacted to help patients and families find and use commu-
nity, state and federal resources for the partially sighted.
Support groups can provide ongoing help and a forum for
sharing feelings, frustrations and solutions.
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EPIDEMIOLOGIJA I KVALITETA @IVOTA PACIJENATA S MAKULARNOM DEGENERACIJOM
S A @ E T A K
Poznato je da makularna degeneracija, pored glaukoma i dijabeti~ke retinopatije, danas predstavlja vode}i uzrok
slabog vida i „sljepo}e« u ~itavom svijetu. Analiziraju se pojedini uzro~ni faktori makularne degeneracije, ali se pored
uobi~ajeno navedenih faktora tako|er daje naglasak i na utjecaj sun~eva svijetla, bez obzira na podru~je spektra, kada
je u pitanju du`e vrijeme eksponiranja kroz `ivot. Nagla{ava se utjecaj stila, na~ina `ivota, kao i va`nost suplementacije
s vitaminima i antioksidansima u razvoju makularne degeneracije.
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